165 related articles for article (PubMed ID: 15234233)
21. C-reactive protein is significantly associated with prostate-specific antigen and metastatic disease in prostate cancer.
Lehrer S; Diamond EJ; Mamkine B; Droller MJ; Stone NN; Stock RG
BJU Int; 2005 May; 95(7):961-2. PubMed ID: 15839913
[TBL] [Abstract][Full Text] [Related]
22. Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years.
Lilja H; Ulmert D; Björk T; Becker C; Serio AM; Nilsson JA; Abrahamsson PA; Vickers AJ; Berglund G
J Clin Oncol; 2007 Feb; 25(4):431-6. PubMed ID: 17264339
[TBL] [Abstract][Full Text] [Related]
23. Prostate-specific antigen: a review of the validation of the most commonly used cancer biomarker.
Hernández J; Thompson IM
Cancer; 2004 Sep; 101(5):894-904. PubMed ID: 15329895
[TBL] [Abstract][Full Text] [Related]
24. Repeating an abnormal prostate-specific antigen (PSA) level: how relevant is a decrease in PSA?
Connolly D; Black A; Murray LJ; Nambirajan T; Keane PF; Gavin A
Prostate Cancer Prostatic Dis; 2009; 12(1):47-51. PubMed ID: 18762815
[TBL] [Abstract][Full Text] [Related]
25. Detection of prostate specific transcripts in the peripheral blood during brachytherapy predicts postoperative PSA kinetics.
Mabjeesh NJ; Amir S; Stenger A; Chen J; Matzkin H
Prostate; 2009 Aug; 69(11):1235-44. PubMed ID: 19434652
[TBL] [Abstract][Full Text] [Related]
26. Detection of prostate-specific antigen coupled to immunoglobulin M in prostate cancer patients.
Beneduce L; Prayer-Galetti T; Giustinian AM; Gallotta A; Betto G; Pagano F; Fassina G
Cancer Detect Prev; 2007; 31(5):402-7. PubMed ID: 18035503
[TBL] [Abstract][Full Text] [Related]
27. Serum human glandular kallikrein 2 (hK2) for distinguishing stage and grade of prostate cancer.
Stephan C; Jung K; Nakamura T; Yousef GM; Kristiansen G; Diamandis EP
Int J Urol; 2006 Mar; 13(3):238-43. PubMed ID: 16643616
[TBL] [Abstract][Full Text] [Related]
28. Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy.
Bastian PJ; Palapattu GS; Lin X; Yegnasubramanian S; Mangold LA; Trock B; Eisenberger MA; Partin AW; Nelson WG
Clin Cancer Res; 2005 Jun; 11(11):4037-43. PubMed ID: 15930338
[TBL] [Abstract][Full Text] [Related]
29. [Prostate-specific antigen--the most important cancer marker. Diagnostics and follow up of prostatic cancer have changed].
Bratt O; Björk T
Lakartidningen; 2007 Nov 14-20; 104(46):3460-4. PubMed ID: 18072615
[No Abstract] [Full Text] [Related]
30. Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends.
Telesca D; Etzioni R; Gulati R
Biometrics; 2008 Mar; 64(1):10-9. PubMed ID: 17501937
[TBL] [Abstract][Full Text] [Related]
31. [The search for better markers for prostate cancer than prostate-specific antigen].
Schenk-Braat EA; Bangma CH
Ned Tijdschr Geneeskd; 2006 Jun; 150(23):1286-90. PubMed ID: 16821452
[TBL] [Abstract][Full Text] [Related]
32. New circulating biomarkers for prostate cancer.
Bensalah K; Lotan Y; Karam JA; Shariat SF
Prostate Cancer Prostatic Dis; 2008; 11(2):112-20. PubMed ID: 17998918
[TBL] [Abstract][Full Text] [Related]
33. Total, free and complexed PSA and hK2 for early detection of prostate cancer.
Haese A; Khan MA; Sokoll LJ
MLO Med Lab Obs; 2003 Jun; 35(6):14-6, 20, 22 passim; quiz 30-1. PubMed ID: 12841068
[No Abstract] [Full Text] [Related]
34. [Prostate specific antigen: utilization modalities and interpretation].
Hannoun-Levi JM; Ginot A; Thariat J
Cancer Radiother; 2008 Dec; 12(8):848-55. PubMed ID: 18539498
[TBL] [Abstract][Full Text] [Related]
35. Biomarkers for prostate cancer detection.
Parekh DJ; Ankerst DP; Troyer D; Srivastava S; Thompson IM
J Urol; 2007 Dec; 178(6):2252-9. PubMed ID: 17936845
[TBL] [Abstract][Full Text] [Related]
36. Antibody array profiling reveals serum TSP-1 as a marker to distinguish benign from malignant prostatic disease.
Shafer MW; Mangold L; Partin AW; Haab BB
Prostate; 2007 Feb; 67(3):255-67. PubMed ID: 17192876
[TBL] [Abstract][Full Text] [Related]
37. Blood biomarkers for prostate cancer detection and prognosis.
Shariat SF; Karam JA; Roehrborn CG
Future Oncol; 2007 Aug; 3(4):449-61. PubMed ID: 17661720
[TBL] [Abstract][Full Text] [Related]
38. [Value of prostate specific antigen in early diagnosis of prostatic cancer].
Xiao LP; Bi XJ; Li YN; Chen XQ; Zhang XF; Yu XP; Liu G; Yang MC; Song Z
Nan Fang Yi Ke Da Xue Xue Bao; 2007 Jan; 27(1):107-8, 112. PubMed ID: 17259162
[TBL] [Abstract][Full Text] [Related]
39. Early detection of prostate cancer in 2007. Part 1: PSA and PSA kinetics.
Schröder FH; Carter HB; Wolters T; van den Bergh RC; Gosselaar C; Bangma CH; Roobol MJ
Eur Urol; 2008 Mar; 53(3):468-77. PubMed ID: 17997011
[TBL] [Abstract][Full Text] [Related]
40. [Screening for prostate cancer: role of PSA in 2006].
Roumeguère T; Peltier A
Rev Med Brux; 2006 Sep; 27(4):S225-31. PubMed ID: 17091883
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
